Fungal endocarditis after transcatheter aortic valve replacement (TAVR): Case report and review of literature

Hiroshi Morioka; Yoshiyuki Tokuda; Hideki Oshima; Mitsutaka Iguchi; Yuka Tomita; Akihiko Usui; Tetsuya Yagi

doi:10.1016/j.jiac.2018.08.017

Fungal endocarditis after transcatheter aortic valve replacement (TAVR): Case report and review of literature

J Infect Chemother. 2019 Mar;25(3):215-217. doi: 10.1016/j.jiac.2018.08.017. Epub 2018 Sep 20.

Authors

Hiroshi Morioka¹, Yoshiyuki Tokuda², Hideki Oshima², Mitsutaka Iguchi³, Yuka Tomita³, Akihiko Usui², Tetsuya Yagi³

Affiliations

¹ Department of Infectious Diseases, Nagoya University Hospital, Japan. Electronic address: morioka-hiroshi@med.nagoya-u.ac.jp.
² Department of Cardiac Surgery, Nagoya University Hospital, Japan.
³ Department of Infectious Diseases, Nagoya University Hospital, Japan.

PMID: 30243901
DOI: 10.1016/j.jiac.2018.08.017

Abstract

The reported number of transcatheter aortic valve replacement-associated infective endocarditis (TAVR-IE) cases has been increasing worldwide, but information about the incidence and clinical features of fungal TAVR-IE is quite limited. We present a patient who acquired TAVR-IE caused by Candida parapsilosis four month after TAVR, who was successfully treated redo-aortic valve replacement and prolonged antifungal therapy.

Keywords: Candida parapsilosis; Fungal endocarditis; Transcatheter aortic valve inplacement; Transcatheter aortic valve replacement.

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antifungal Agents / therapeutic use
Candida parapsilosis
Candidiasis, Invasive* / diagnosis
Candidiasis, Invasive* / drug therapy
Candidiasis, Invasive* / etiology
Candidiasis, Invasive* / surgery
Endocarditis* / diagnosis
Endocarditis* / drug therapy
Endocarditis* / etiology
Endocarditis* / surgery
Humans
Male
Reoperation
Transcatheter Aortic Valve Replacement / adverse effects*

Substances

Antifungal Agents